Financial Data and Key Metrics Changes - For Q3 FY2025, revenue decreased by 38% to $8.4 million compared to $13.6 million in the prior year period [11] - For the nine months ended June 30, 2025, revenue decreased by 5% to $43.3 million compared to $45.7 million in the prior year period [11] - Net loss attributable to common stockholders for Q3 FY2025 was $18.3 million, compared to a loss of $2 million in the same period last year [14] - EBITDA for Q3 FY2025 was $19.2 million, compared to $1.3 million for Q3 FY2024 [16] - Cash and cash equivalents increased to $42.1 million as of June 30, 2025, from $3.2 million at the end of FY2024 [16] Business Line Data and Key Metrics Changes - Citrus harvest volumes for Q3 FY2025 were approximately 2.1 million pound solids, down from 4.3 million pound solids in Q3 FY2024 [11] - Land Management and other operations revenue increased by 5768% for Q3 FY2025, primarily due to increased rock and sand royalty income and sod sales [12] - The company completed its last major citrus harvest in April 2025, marking a shift away from capital-intensive citrus operations [5][18] Market Data and Key Metrics Changes - The company achieved $9.3 million from combined land and equipment sales in Q3 FY2025, with year-to-date land sales reaching $23.5 million, exceeding the original guidance of $20 million [6][20] - The estimated present value of near-term real estate development projects is between $335 million and $380 million, representing significant value from just 10% of land holdings [9] Company Strategy and Development Direction - The company is transitioning to a diversified land company model, focusing on land development and diversified usage strategies [5][18] - The approval of House Bill 4,041 for the Corkscrew Grove Stewardship District is a significant regulatory milestone that supports the company's development strategy [7][19] - The company is maintaining a balance between high-value property development and diversified agricultural operations [10][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver enhanced long-term returns for shareholders, with expectations of approximately $20 million in adjusted EBITDA for FY2025 [20][21] - The company is positioned to end the fiscal year with at least $25 million in cash and sufficient liquidity to fund operations through FY2027 [20] Other Important Information - The company has no significant debt maturities until 2029, with total debt at $85.2 million and net debt at $43.2 million as of June 30, 2025 [17] Q&A Session Summary Question: Are you currently in discussions for additional land sales? - Management indicated that discussions are ongoing, but the timing for closing these transactions is uncertain, potentially rolling into FY2026 [25][26] Question: What are potential milestones to watch for regarding Corkscrew? - Management noted that external variables could affect the entitlement process, but they remain confident in the timeline for securing permits [27][28] Question: Will Alico partner with other groups on development? - Currently, Alico is handling the entitlement process independently, with no immediate need for partners, but they have options for future partnerships [29][30][31]

Financial Data and Key Metrics Changes - Consolidated revenue for Q2 2025 was $138.1 million, slightly higher than Q2 2024, reflecting ongoing customer deferral of major capital spending due to market uncertainty [21] - GAAP gross margin was 43.1%, down from 43.8% in the same period last year, while non-GAAP gross margin was 47.7%, down from 49% [22] - GAAP operating loss for the quarter was $16.6 million, an improvement from a loss of $26 million in the same period last year, while non-GAAP operating income was $1.1 million compared to a loss of $3.2 million [23][24] - Cash flow used in operating activities was $1.1 million, an improvement from $2.4 million in Q2 2024, with an expectation of positive operating cash flow for the full year 2025 [24] Business Line Data and Key Metrics Changes - Product revenue was $94.8 million, up from $93.6 million in the same period last year, while service revenue was $43.3 million, down from $44.4 million [21] - Within product revenue, system revenue increased to $30.6 million from $29 million, and consumables revenue was $64.2 million, slightly down from $64.6 million but up 2.6% sequentially [21] Market Data and Key Metrics Changes - Customer engagement remains strong despite macroeconomic challenges, with ongoing investment in R&D and new technology offerings [6][20] - The company launched the North American Stratasys Tooling Center to help manufacturers validate and scale additive manufacturing applications [9] Company Strategy and Development Direction - The long-term growth strategy focuses on capturing opportunities in high-growth sectors influenced by megatrends such as supply chain localization and sustainability [7][8] - The company emphasizes innovation and execution, aiming to solidify its leadership in digital manufacturing as market dynamics stabilize [6][30] Management's Comments on Operating Environment and Future Outlook - Management noted that customer spending remains challenged, impacting near-term business views, but the long-term outlook remains positive [19][20] - The return to normalized capital spending has been delayed, with expectations for significant opportunities in production applications to close potentially moving into 2026 [25][26] Other Important Information - The company ended the quarter with $254.6 million in cash and equivalents, bolstered by a $120 million investment [25] - New material offerings include P3 Silicon 25A, designed for the Stratasys Origin DLP platform, enhancing capabilities in industrial 3D printing [16] Q&A Session Summary Question: Can you clarify which specific verticals or regions are seeing the most pronounced slowdown or delays? - Management clarified that there is no slowdown, only delays, particularly in larger production application deals which have longer sales cycles [32][34] Question: What assumptions are baked into the fourth quarter adjusted EBITDA margin? - The guidance for Q4 is largely based on cost monitoring and reductions, with no large deals factored into the model [39][40] Question: What is impacting the gross margin? - Gross margin changes are attributed to sales mix changes, inventory absorption issues, and tariff impacts [43][46] Question: Can you elaborate on the Nexa asset acquisition? - The acquisition included valuable IP and R&D knowledge, positioning the company stronger in key use cases [56][59] Question: Do you anticipate additional partnerships with other vehicle OEMs? - Management expressed optimism about expanding partnerships, leveraging proven use cases from collaborations with GM and Toyota [72][74]

Financial Data and Key Metrics Changes - Revenue for the second quarter was $1,200,000, reflecting a 40% increase from the first quarter and matching the previous quarterly high [9][39] - The cash balance at the end of the second quarter was $31,100,000, with a quarterly burn rate of $10,300,000, slightly better than the average burn rate of the previous four quarters [39][40] - Non-GAAP net loss for the second quarter was $9,900,000, which is an improvement of $1,200,000 sequentially [45] Business Line Data and Key Metrics Changes - EtherCAT test volume for the second quarter was 2,756 tests, within the target range of 2,500 to 3,000 tests per quarter [7] - The company invoiced nearly $7,000,000 for 2,756 tests, with revenue recognized at approximately $1,200,000, indicating a 40% sequential revenue increase and a 19% year-over-year increase [42][47] Market Data and Key Metrics Changes - The company is targeting a Medicare population that constitutes approximately 40% to 50% of the 30 million patients recommended for screening under existing guidelines [57] - Currently, the Medicare portion of testing is running in the 10% to 15% range, primarily due to a lack of targeted efforts [58] Company Strategy and Development Direction - The company is focused on securing Medicare coverage, which is seen as a critical milestone for accelerating commercialization efforts [6][36] - A Multi X Contractor Advisory Committee (CAC) meeting is scheduled for September 4, which is viewed as a significant step towards achieving a positive Medicare coverage policy outcome [12][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming CAC meeting and the potential for a positive outcome regarding Medicare coverage [36][54] - The company is taking proactive steps to prepare for increased Medicare patient engagement once coverage is secured [36][59] Other Important Information - The company has strengthened its balance sheet with a public offering that netted $16,100,000 in proceeds, providing sufficient resources to ramp up commercial efforts after securing Medicare approval [15][39] - The publication of a pilot study in the American Journal of Gastroenterology highlighted the effectiveness of EsoGuard, which could expand the total addressable market significantly if similar results are replicated in ongoing studies [16][18] Q&A Session Summary Question: Insights on the multi-jurisdictional CAC meeting - Management indicated that the meeting is a positive sign of collaboration among Medicare contractors, suggesting they are in the late stages of the coverage determination process [52][53] Question: Percentage of business currently from Medicare - Currently, the Medicare portion of testing is around 10% to 15%, with plans to increase this significantly once Medicare coverage is secured [58][59] Question: Timing expectations post-CAC meeting - Management expects a draft LCD to be published relatively quickly after the CAC meeting, with a comment period following that [62][70]

Lucid Diagnostics (LUCD) Q2 2025 Earnings Call August 13, 2025 08:30 AM ET Speaker0Good morning, and welcome toSpeaker1theSpeaker0Lucid Diagnostics Second Quarter twenty twenty five Business Update Conference Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. Please note that this event is being recorded. I would now like to turn the conference over to Matt Reilly, Lucid Diagnostics' Senior Director of Investor Relations.Please ...

Financial Data and Key Metrics Changes - The company generated revenues of $20.1 million for Q2 2025, with a gross margin of 21.4%, down from 27% in the prior year period [14][15] - Total operating expenses increased to $16.8 million from $14.5 million year-over-year, primarily due to higher corporate expenses and increased depreciation and R&D expenses [16][17] - Adjusted EBITDA was negative $8.7 million, compared to negative $3.9 million in the prior year [17] - Free cash flow improved to an outflow of $5.2 million from negative $11.5 million year-over-year [18] - The company ended the quarter with total liquidity of $36.2 million, including $35 million available under an undrawn credit line [18][19] Business Line Data and Key Metrics Changes - The backlog of orders reached a record $43 million to be shipped in 2025, indicating strong customer demand [6][14] - The aeronautics segment is the largest contributor to the backlog, with $21.3 million associated with this division [48] - The warehouse division reported a gross margin of 23%, down from 37% in the prior year, reflecting lower segment revenue and a change in product mix [15] Market Data and Key Metrics Changes - The global automotive smart glass market is projected to grow from $16 billion in 2024 to over $25 billion by 2028, with the company positioned to capitalize on this growth [8] - The marine lab market is valued at $6.2 billion, with the company expanding its presence in this sector [9] Company Strategy and Development Direction - The company aims to strengthen its balance sheet through debt financing, having closed on $15 million under favorable terms [5][19] - Strategic expansion into the marine sector and the aeronautics division is a focus, with new product launches planned for early 2026 [10][11] - The company is committed to non-dilutive capital sources to fund operations until achieving cash flow profitability [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting full-year guidance despite shipment delays due to external factors, including a conflict in the region [6][29] - The second half of 2025 is expected to be significantly stronger than the first half, supported by a record backlog of orders [6][20] - Management emphasized the importance of operational discipline and cash management strategies to improve cash flow productivity [18] Other Important Information - The company has made significant board changes to align with its public company evolution, welcoming back a former director with expertise in global expansion and M&A [12] - The company is focused on enhancing its innovation pipeline across all business divisions [23] Q&A Session Summary Question: Can you elaborate on the timing dynamics affecting revenue? - Management acknowledged shifts in delivery timing and expressed confidence in meeting annual guidance despite some deliveries moving to the second half of the year [26][29] Question: What is the confidence level for the second half revenue ramp? - Management confirmed the company is prepared to deliver $45 million to $50 million quarters, aligning with sales order cadence [31][32] Question: Can you discuss liquidity dynamics going forward? - Management highlighted a $35 million credit line available for use and expressed confidence in achieving cash flow positive status [36][38] Question: What are the levers expected to achieve positive EBITDA this year? - Management indicated that achieving over $31 million in revenue would lead to positive adjusted EBITDA, with improved gross margins expected in the second half [43][45] Question: How does the backlog mix look for key contributors? - The aeronautics segment is the largest contributor to the backlog, with management confident in meeting targets for this division [47][48] Question: How will working capital items change to support increased shipping capacity? - Management noted that 80% of the business is factored, allowing for immediate cash flow upon invoicing, which supports production planning [50][52]

Financial Data and Key Metrics Changes - Total revenue declined by 18% year on year due to strategic restructuring and increased point redemption by customers [5][6][21] - The elevated effective tax rate was primarily due to non-deductibility of some executive compensation and temporary timing differences in aircraft sales recognition [6][7] Business Line Data and Key Metrics Changes - The average customer spending is trending lower than last year, but there are early signs of recovery in certain areas such as the gorilla clinic [5][6] - The Jun clinic and Neo Skin clinic are achieving an average spend per customer that exceeds existing clinics, indicating strong growth potential [12][13] Market Data and Key Metrics Changes - The aesthetics medicine industry in Japan is experiencing severe competition, yet customer visits have increased to 6,310,000 annually, with a high repeat rate of 72% [4][5] - The dermatological aesthetics segment is showing a higher growth rate, presenting significant growth potential [10] Company Strategy and Development Direction - The company is implementing a multi-brand strategy tailored to different market segments to meet diverse customer needs [10][14] - The focus is on enhancing the medical tourism business, particularly targeting Chinese tourists [15] - The company aims to expand its clinic network from 260 to 1,000 clinics over the next ten years [32] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that while there were negative factors impacting performance, they believe the business will improve moving forward [35][41] - The company is entering a phase of growth investment after completing business restructuring [44] Other Important Information - The company conducted its first-ever share buyback from May to July, which positively impacted share price and liquidity [22][44] - The company is considering new share issuance and partial sale by the founder to improve accessibility for a broader investor base [22][46] Q&A Session Summary Question: Are the new clinics starting up as planned? - Newly opened clinics are seeing steady customer visits, with an increase in male customers noted [24][25] Question: What is the future pricing trend? - The company is adopting a multi-brand strategy with different pricing tiers to meet varying customer needs [26] Question: Can you explain the growth strategy regarding organic and inorganic growth? - The company plans to proactively open new clinics and conduct M&A, with a strong track record of turning around acquired clinics [27][29] Question: How many clinics are you planning to open in Japan? - The company aims to increase the number of clinics to 1,000 over the next ten years [32] Question: What is the outlook for future profitability? - The company expects to secure sufficient margins and improve overall profitability as new clinics are established [34] Question: How is the company addressing the current share price trend? - The company is focusing on improving liquidity through share buybacks and considering dividend payments [43][44] Question: What are the plans for the CEO's shareholding? - The CEO is considering selling shares to improve liquidity and fund investments [46]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $3.4 million, a decrease from $11.8 million in Q2 2024, primarily due to distributor transitions and lower investments in sales and marketing [17][19] - Gross profit for the second quarter was $2.5 million, or 74% of revenue, compared to $9 million, or 76% of revenue in the same period in 2024 [17] - Operating expenses decreased by 48% year-over-year, leading to an operating loss improvement of 26% compared to the prior year [16][19] Business Line Data and Key Metrics Changes - Clinics utilizing the combination approach for obesity management grew by 20% compared to 2024, indicating potential for future growth [15] - Sales and marketing expenses were reduced to $2.4 million from $6.7 million in Q2 2024, reflecting increased operational efficiency [18] - Research and development expenses decreased to $1.8 million from $4.3 million in Q2 2024, driven by cost reductions related to the Audacity trial [18] Market Data and Key Metrics Changes - The company is focusing on international markets where GLP-1s are less expensive, which is expected to drive adoption of the combination therapy [24][30] - The U.S. market presents a significant opportunity, with 40% of adults classified as obese, yet only 8 million currently using injectable obesity therapy [15] Company Strategy and Development Direction - The new strategy emphasizes metabolically healthy weight loss through combination therapy of the Allurion balloon and low-dose GLP-1s [6][7] - The company is transitioning away from distribution partners lacking access to accounts that can deliver comprehensive obesity care, focusing instead on high-performing accounts [9][10] - A term sheet was signed with a strategic partner to expand manufacturing capabilities and explore the development of a novel GLP-1 drug-eluting intragastric balloon [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the transition to the new strategy may cause short-term disruptions but believes it will lead to long-term growth [15][16] - The company is optimistic about the potential for FDA approval of its PMA submission, which could accelerate its U.S. market entry [37] - Management is confident that the combination therapy will establish a new standard of care in obesity management [21] Other Important Information - Cash and cash equivalents as of June 30, 2025, were $12.7 million, providing a runway for future operations [19] - The company anticipates recording charges of approximately $1.5 million related to the new strategic direction [16] Q&A Session Summary Question: How should we think about low-dose GLP-1s plus Allurion gastric balloon impacting overall costs for obesity care? - Management noted that GLP-1s are inexpensive internationally, and combining them with the Allurion program incurs minimal costs for patients, driving adoption [24][30] Question: Can you provide guidance on operating expenses for R&D and G&A? - Management indicated that R&D expenses of $1.8 million are appropriate for the near term, with overall operating expenses expected to decrease by approximately 50% due to restructuring [41][42] Question: What is the cash runway associated with the U.S. launch? - Management stated that cash needs will depend on the commercial strategy in the U.S., but they feel confident about the current cash position [45][46] Question: How will the new strategy impact reengagement with accounts in France? - Management expressed optimism that the combination therapy approach will positively impact reengagement with accounts in France, especially as GLP-1s become more accessible [51]

Similarweb (SMWB) Q2 2025 Earnings Call August 13, 2025 08:30 AM ET Speaker0Greetings. Welcome to SimilarWeb's Second Quarter Fiscal twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation today. Please note, this conference is being recorded.I will now turn the conference over to Rami Myerson, Vice President, Investor Relations. Thank you. You may now begin.Speaker1Thank you, operator. Welcome everyone to ...

Financial Data and Key Metrics Changes - The fleet-wide time charter equivalent (TCE) was approximately $50,500 per vessel per day, with VLCCs at nearly $50,000 and Suezmaxes at $51,500 [3] - Adjusted EBITDA for the quarter was $47.3 million, with an adjusted net profit of $26.7 million and adjusted EPS of $0.83 [3] - TCE revenue for the six-month period was $113 million, with EBITDA close to $80 million and reported net income exceeding $39 million or $1.23 per share [4] - The company ended the quarter with $65 million in cash and total debt of $631 million, resulting in a book leverage of 57% and a market-adjusted net loan-to-value (LTV) of around 40% [4] Business Line Data and Key Metrics Changes - The company operates a fleet of 14 vessels, including six Suezmaxes and eight VLCCs, with an average age of 5.9 years, making it the youngest fleet among listed crude tanker peers [5] - The company achieved 100% utilization in both VLCC and Suezmax segments, with a significant increase in TCE quarter-on-quarter [12] Market Data and Key Metrics Changes - The market has eased compared to Q2, but the outlook remains optimistic for Q4, with 77% of RVs fixed in the spot market at $44,200 per day [15] - The Suezmax market is currently firm, with expectations of fixing voyages at rates higher than Q3 guidance [15] - OPEC is expected to unwind production cuts, leading to increased tanker utilization [20] Company Strategy and Development Direction - The company aims to become the public platform of choice within the crude oil tanker space, focusing on expanding its investor base and enhancing its capital structure [10] - Recent refinancing transactions have lowered financing margins and extended average maturities, which is expected to result in annual interest savings of around $1 million [8] Management's Comments on Operating Environment and Future Outlook - Management expressed a constructive outlook for the remainder of the year, citing supportive market dynamics and the potential for increased demand due to OPEC's production adjustments [29] - The company noted that the supply side remains structurally tight, particularly for large vessels, which is expected to support tanker earnings in the coming years [22] Other Important Information - The company declared a dividend of $0.70 per share, marking the fifteenth consecutive distribution, with total distributions over the last four quarters amounting to $1.82 per share [3] - The company has been actively cleaning vessels for diesel trade, which has provided unique opportunities in the spot market [34] Q&A Session Summary Question: Overview of the VLCC that was cleaned for diesel trade - Management indicated that the vessel will likely return to loading crude cargo after the diesel voyage, emphasizing their unique ability to clean vessels themselves [34] Question: Impact of OPEC production increases on cargo availability - Management confirmed that cargoes are returning to the market, with VLCC rates experiencing a significant increase recently [40] Question: Economics of cleaning vessels and market conditions - Management explained that the profitability of cleaning vessels depends on the spread between clean and dirty rates, with specific conditions required for it to be economically viable [48] Question: Future of Russian crude imports and market dynamics - Management suggested that a shift in import preferences could lead to increased Russian crude sales to China, impacting ton miles and trade flows [75] Question: Operating costs and exchange rate impacts - Management noted that operating costs have increased due to euro-based expenses and exchange rate fluctuations, but overall costs are expected to remain relatively flat [68]

ARS Pharmaceuticals (SPRY) Q2 2025 Earnings Call August 13, 2025 08:30 AM ET Speaker0Good morning and welcome to the ARS Pharmaceuticals Conference Call. At this time, all participants are in a listen only mode. After the company's prepared remarks, we'll open the line for questions. Please be advised that this conference is being recorded. I'll now turn the call over to Justin Chalka, Chief Business Officer.Please go ahead.Speaker1Good morning, and thank you for joining our second quarter twenty twenty fiv ...